Name /Acepodia Inc.
Address /Rm. 7, 17F., No.99, Sec. 1, Sintai 5th Rd.,Sijhih Dist., New Taipei City 22175,Taiwan (R.O.C.)
Name /Joseph S. McCracken
Title /Senior Vice President of Business Development
Telephone /(Work) +1(415)3667822 / +886-2-26976100
Acepodia was founded in 2017 by Dr. Patrick Y. Yang, former EVP of Juno Therapeutics, Roche and Genentech, and by Dr. Sonny Hsiao, UC Berkeley Cell Biologist and inventor of Acepodia’s core technology. Acepodia is a privately held biotechnology company focused on developing novel, targeted, allogeneic cell therapies to treat cancers.
Acepodia is pioneering next-generation technologies that effectively fight cancers. The company is developing first-in-class, off-the-shelf allogeneic cell therapies with significantly improved potency, better safety and broad applicability across hematologic and solid tumor cancers.
Acepoida’s ACC™ platform simply and cost effectively links antibodies directly to immune cells, enhancing their tumor-killing ability without the need for genetic manipulation.
Relative to other cellular immunotherapy approaches, ACC™ requires no genetic engineering of immune cells, and has a substantially improved dose-titration capability. Broadly tested with various existing antibodies, ACC™ is capable of arming effector cells with available antibodies.
Acepodia is employing a flexible therapeutic design that leverages cutting edge technologies to develop the next generation of off-the-shelf cell therapies by supercharging select oNK cells and gamma delta (γδ) T cells to target and engage cancer cells.
ACE1702 is an off-the-shelf oNK cell therapy conjugated with HER2 antibodies that overcomes the limitations of current cancer cell therapies by enhancing the innate ability of NK cells to target and destroy HER2-expressing tumors. Acepodia has initiated a Phase 1 clinical trial of ACE1702 in the U.S.. ACE1831 is an off-the-shelf gamma delta T cell therapy candidate that targets CD20-expressing hematological cancers using anti-CD20 antibody conjugated gamma delta T cells. Taking advantage of the nature of gamma delta T cells to scavenge the malignant blood cells, ACE1831 has demonstrated in models enhanced cytotoxicity against cancer cells both in vitro and in vivo. ACE1831 is currently under evaluation in preclinical studies and planned to enter Phase 1 in 2021.
Name /Sean Liu